Yahoo Web Search

Search results

1. • 

     Home Phototherapy for Psoriasis: Optimizing Access

     Medscape· 21 hours ago

     Supporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of...

2. • 

     Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief

     Verywell Health via Yahoo News· 1 day ago

     With two kids under 2, I needed some relief. I had been through enough psoriasis treatment and had...

3. • 

     Nail Psoriasis

     Health via Yahoo News· 6 days ago

     Biopsy: Your provider might collect a biopsy (small skin sample) from the nail bed and send it to a laboratory for evaluation. Nail Psoriasis Treatment...

4. • 

     BMS reports four-year data from psoriasis treatment extension trial

     Clinical Trials Arena via Yahoo Finance· 6 days ago

     The study followed the Phase III POETYK PSO-1 and POETYK PSO-2 trials...remained consistent over the...

5. • 

     InnoCare Pharma concludes subject enrolment Phase II psoriasis trial

     Clinical Trials Arena via Yahoo Finance· 7 days ago

     InnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of...

6. • 

     J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial

     Clinical Trials Arena via Yahoo Finance· 2 days ago

     J&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...

7. • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

     Morningstar· 2 days ago

     “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey...

8. • Ultravate side effects: What they are and how to manage them

     Healthline· 3 days ago

     Ultravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to ...

9. • TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...

     FOX 23 News Albany· 3 days ago

     WASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...

10. • AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...

      Tri-County Times· 6 days ago

      - AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)